PAH and phenylketonuria: Since 1999, it has been widely reported that pharmacological doses of tetrahydrobiopterin (BH4), the cofactor for phenylalanine hydroxylase (PAH) enzyme, can reduce blood Phe levels in many PKU patients, allowing for dietary relaxation or even cessation [9,21].